A Phase 2-3, Multicenter, Randomized, Double-blind study of Selinexor (KPT-330) Versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A study for patients with advanced unresectable dedifferentiated liposarcoma (DDLS) using study drug Selinexor
Sponsor: Karyopharm Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAQ6101
U.S. Govt. ID: NCT02606461
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a Phase 2-3 study evaluating the effects of selinexor in patients with advanced unresectable dedifferentiated liposarcoma (DDLS). This study drug selinexor works by trapping tumor suppressing proteins within the nucleus of the cells and thus causing the cancer cells to die or stop growing. Selinexor has previously been tested in humans to define a safe dose to be administered. It is not known at this time if selinexor will treat your cancer. Selinexor is currently being tested in other clinical trials in patients with advanced cancers. This study will examine the effects of selinexor on your cancer and on your body including any side-effects that you may experience.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with dedifferentiated liposarcoma (DDLS)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator